Cord Blood News Volume 4.27 | Jul 12 2012

A Quantitative Proteomic and Transcriptomic Comparison of Human Mesenchymal Stem Cells from Bone Marrow and Umbilical Cord Vein
Total protein extracts of bone marrow-human mesenchymal stem cells (hMSCs) and umbilical cord vein-hMSCs were quantitatively compared using gel-LC-MS/MS. [Proteomics] Abstract

A Novel Automated Bioreactor for Scalable Process Optimization of Hematopoietic Stem Cell Culture
Investigators demonstrated the potential of a new, automated, 24 × 15 mL replicate suspension bioreactor system, with online monitoring and control, to develop an hematopoietic stem cell proliferation and differentiation process for erythroid committed cells. [J Biotechnol] Abstract

MicroRNAs Can Increase the Efficiency of Ex Vivo Platelet Generation
Researchers derived a highly efficient differentiation protocol to produce mature polyploid megakaryocytes and functional platelets from CD34⁺-hematopoietic stem and progenitor cells by comparing previously published approaches. The potency of this novel megakaryocytic differentiation protocol was validated using cord blood and peripheral blood human hematopoietic stem and progenitor cells. [Ann Hematol] Abstract

Dynamic Expression of Specific miRNAs during Erythroid Differentiation of Human Embryonic Stem Cells
Scientists aimed to identify erythroid lineage-specific microRNAs (miRNAs) expressed during in vitro erythropoiesis using human embryonic stem cells and human umbilical cord blood CD34+ cells. [Mol Cells] Abstract

Isolation and Characterization of Mesenchymal Stem Cells from Whole Human Umbilical Cord Applying a Single Enzyme Approach
Researchers showed that human umbilical cord-mesenchymal stem cells were easily isolated by a single enzymatic digestion and characteristic of plastic adherence and fibroblast-like morphology. [Cell Biochem Funct] Abstract

Genetic Regulation on Ex Vivo Differentiated Natural Killer Cells from Human Umbilical Cord Blood CD34⁺ Cells
Investigators performed an extended analysis of transcription factors during in vitro differentiation of natural killer cells. [J Recept Signal Transduct Res] Abstract

Co-Culture of Vascular Endothelial Cells and Adipose-Derived Stem Cells as a Source for Bone Engineering
The authors examined the influence of co-culturing vascular endothelial cells (VECs) and adipose-derived stem cells (ADSCs) on osteogenic differentiation. Cord blood-derived VECs and ADSCs were isolated from rats and characterized with immunofluorescence staining and morphological observation. [Ann Plast Surg] Abstract

In Vivo Differentiation of Human Amniotic Epithelial Cells into Cardiomyocyte-Like Cells and Cell Transplantation Effect on Myocardial Infarction in Rats: Comparison with Cord Blood and Adipose Tissue-Derived Mesenchymal Stem Cells
Researchers assessed whether human amniotic epithelial cells (h-AECs) could differentiate into cardiomyocytes in vivo and whether h-AECs transplantation can decrease infarct size and improve cardiac function, in comparison to transplantation of cord blood-derived mesenchymal stem cells (MSCs) or adipose tissue-derived MSCs. [Cell Transplant] Abstract

Cryo-Save Arabia Now U.S. Food and Drug Administration (FDA) Registered
Cryo-Save Arabia’s lab, located in Dubai, is now FDA registered for autologous and family-related use of umbilical cord blood stem cells. [Cryo-Save AG] Press Release

PerkinElmer Collaborates with the European Foundation for the Care of Newborn Infants (EFCNI) to Increase Pre-Eclampsia Screening Awareness
PerkinElmer, Inc. announced that it has entered into a collaboration with the EFCNI to increase and improve awareness of pre-eclampsia screening throughout Europe. [PerkinElmer, Inc.] Press Release

Death of Evidence Announcement
To make the public aware of government cuts to federal science programs, Canadians organized a ‘Death of Evidence’ rally to coincide with a large scientific conference taking place in Ottawa. [Death of Evidence, Canada] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Chief Scientific Officer (SynGen Inc.)

Group Leaders, Principle Scientists – Stem Cell Clinical Product R&D (Shanghai Hengrui Pharmaceuticals Co., Ltd)

Stem Cell Therapy Scientist (Paramount Recruitment)

BMS Specialist/BMS Advanced Specialist (NHS Blood and Transplant)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.